{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:48:15Z","timestamp":1787028495224,"version":"build-2736575974"},"reference-count":75,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T00:00:00Z","timestamp":1672963200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Surgical Skills Ltd., Manchester, UK"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Transplant-associated thrombotic microangiopathy (TA-TMA) constitutes a significant contributor to the increased morbidity and mortality after allogenic hematopoietic stem cell transplantation (allo-HSCT). TA-TMA is a heterogenous disease, characterized by the triad of endothelial cell activation, complement dysregulation and microvascular hemolytic anemia, which may affect all organs. The lack of consensus diagnostic criteria, along with the common clinical features mimicking other diseases that complicate allo-HSCT, make the diagnosis of TA-TMA particularly challenging. Significant effort has been made to recognize specific risk factors predisposing to the development of TA-TMA and to identify serum biomarkers predicting the development of the disease. With regard to treatment, therapeutic plasma exchange (TPE) has been traditionally used, although with doubtful efficacy. On the other hand, the pivotal role of complement activation in the pathophysiology of TA-TMA has led to the exploration of the therapeutic potential of complement inhibitors in this setting. Eculizumab has been proposed as a first-line therapeutic agent in TA-TMA, owing to the very promising results in both pediatric and adult clinical trials. Pharmacokinetic and pharmacodynamic studies and CH50 levels are of paramount importance in the allo-HSCT setting, as a different dosing schedule (more intensive\u2014in dose and frequency\u2014at the beginning) seems to be required for successful outcomes. Furthermore, Narsoplimab, a MASP-2 inhibitor, recently received a Breakthrough Therapy Designation from the FDA for the treatment of TA-TMA after allo-HSCT. Finally, the decision to withdraw the CNIs, although initially advised by the Bone and Marrow Transplant Clinical Trials Network Committee, remains debatable owing to the controversial results of recent clinical trials. This review summarizes the current updates on pathophysiology, diagnosis and therapeutic approaches and emphasizes future goals and perspectives.<\/jats:p>","DOI":"10.3390\/ijms24021159","type":"journal-article","created":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T02:09:39Z","timestamp":1673230179000},"page":"1159","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Transplant-Associated Thrombotic Microangiopathy in the Context of Allogenic Hematopoietic Stem Cell Transplantation: Where We Stand"],"prefix":"10.3390","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5162-1304","authenticated-orcid":false,"given":"Ioanna","family":"Lazana","sequence":"first","affiliation":[{"name":"Cell and Gene Therapy Laboratory, Biomedical Research Foundation of the Academy of Athens, 11527 Athens, Greece"},{"name":"Hematology Department, King\u2019s College Hospital NHS Foundation Trust, London SE5 9RS, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,1,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMra052638","article-title":"Hematopoietic stem-cell transplantation","volume":"354","author":"Copelan","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_2","first-page":"126","article-title":"Death after hematopoietic stem cell transplantation: Changes over calendar year time, infections and associated factors","volume":"55","author":"Ebmt","year":"2019","journal-title":"Bone Marrow Transplant."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-021-07897-3","article-title":"Early transplantation-related mortality after allogeneic hematopoietic cell transplantation in patients with acute leukemia","volume":"21","author":"Kong","year":"2021","journal-title":"BMC Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1016\/j.bbmt.2016.05.019","article-title":"Late Mortality and Causes of Death among Long-Term Survivors after Allogeneic Stem Cell Transplantation","volume":"22","author":"Atsuta","year":"2016","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/hon.2346","article-title":"Transplant-associated thrombotic microangiopathy: An unresolved complication of unrelated allogeneic transplant for hematologic diseases","volume":"35","author":"Sakellari","year":"2016","journal-title":"Hematol. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/s41409-018-0293-3","article-title":"High mortality in hematopoietic stem cell transplant-associated thrombotic microangiopathy with and without concomitant acute graft-versus-host disease","volume":"54","author":"Kraft","year":"2018","journal-title":"Bone Marrow Transplant."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1016\/j.bbmt.2018.05.010","article-title":"Impact of Thrombotic Microangiopathy on Renal Outcomes and Survival after Hematopoietic Stem Cell Transplantation","volume":"24","author":"Postalcioglu","year":"2018","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e13371","DOI":"10.1111\/ctr.13371","article-title":"Transplant-associated thrombotic microangiopathy: Incidence, prognostic factors, morbidity, and mor-tality in allogeneic hematopoietic cell transplantation","volume":"32","author":"Gavriilaki","year":"2018","journal-title":"Clin. Transpl."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1111\/bjh.16457","article-title":"Incidence, Risk Factors for and Outcomes of Transplant-Associated Thrombotic Microangiopathy","volume":"189","author":"Epperla","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1182\/bloodadvances.2019000143","article-title":"Allogeneic reactivity\u2013mediated endothelial cell complications after HSCT: A plea for consensual definitions","volume":"3","author":"Pagliuca","year":"2019","journal-title":"Blood Adv."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1038\/s41409-021-01390-y","article-title":"Endothelial cell dysfunction: A key determinant for the outcome of allogeneic stem cell transplantation","volume":"56","author":"Luft","year":"2021","journal-title":"Bone Marrow Transplant."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.bbmt.2012.09.018","article-title":"Endothelial Vulnerability and Endothelial Damage Are Associated with Risk of Graft-versus-Host Disease and Response to Steroid Treatment","volume":"19","author":"Dietrich","year":"2012","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1200\/JCO.2013.54.4056","article-title":"Single-Nucleotide Polymorphisms Within the Thrombomodulin Gene (THBD) Predict Mortality in Patients With Graft-Versus-Host Disease","volume":"32","author":"Rachakonda","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1097\/01.tp.0000230373.82376.46","article-title":"Risk Factors and Severe Outcome in Thrombotic Microangiopathy After Allogeneic Hematopoietic Stem Cell Transplantation","volume":"82","author":"Uderzo","year":"2006","journal-title":"Transplantation"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.bbmt.2005.07.012","article-title":"Hemolytic Uremic Syndrome after Bone Marrow Transplantation: Clinical Characteristics and Outcome in Children","volume":"11","author":"Hale","year":"2005","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1038\/bmt.2017.39","article-title":"Transplant-associated thrombotic microangiopathy: Opening Pandora\u2019s box","volume":"52","author":"Gavriilaki","year":"2017","journal-title":"Bone Marrow Transplant."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"183","DOI":"10.2165\/00003495-200969020-00004","article-title":"Thrombotic microangiopathy in haematopoietic stem cell transplantation: Diagnosis and treatment","volume":"69","author":"Choi","year":"2009","journal-title":"Drugs"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1182\/blood-2014-03-564997","article-title":"Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: A study in children and young adults","volume":"124","author":"Jodele","year":"2014","journal-title":"Blood"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1002\/ajh.25922","article-title":"Characteristics of late transplant-associated thrombotic microangiopathy in patients who underwent al-logeneic hematopoietic stem cell transplantation","volume":"95","author":"Heybeli","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1046\/j.1365-2141.2002.03721.x","article-title":"Thrombotic thrombocytopenic purpura after allogeneic stem cell transplantation: A survey of the European Group for Blood and Marrow Transplantation (EBMT)","volume":"118","author":"Ruutu","year":"2002","journal-title":"Br. J. Haematol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1097\/TP.0b013e3181f24e8d","article-title":"Validation of recently proposed consensus criteria for thrombotic microangiopathy after allogeneic hema-topoietic stem-cell transplantation","volume":"90","author":"Cho","year":"2010","journal-title":"Transplantation"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e487","DOI":"10.1097\/HS9.0000000000000487","article-title":"Endothelial and Complement Activation As Predictors of Survival in Adult Allogeneic Hematopoietic Cell Transplantation","volume":"5","author":"Gavriilaki","year":"2020","journal-title":"Hemasphere"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.bbmt.2018.10.015","article-title":"Transplant-Associated Thrombotic Microangiopathy Is a Multifactorial Disease Unresponsive to Immunosup-pressant Withdrawal","volume":"25","author":"Li","year":"2019","journal-title":"Biol Blood Marrow Transpl."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1038\/s41409-021-01283-0","article-title":"Transplant-associated thrombotic microangiopathy: Theoretical considerations and a practical approach to an unrefined diagnosis","volume":"56","author":"Young","year":"2021","journal-title":"Bone Marrow Transplant."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1016\/j.transproceed.2021.07.043","article-title":"Predictors of Transplant-Associated Thrombotic Microangiopathy in Patients With Overlap or Chronic Graft-vs-Host-Disease","volume":"53","author":"Gavriilaki","year":"2021","journal-title":"Transplant. Proc."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"695037","DOI":"10.3389\/fimmu.2021.695037","article-title":"Early Elevation of Complement Factor Ba Is a Predictive Biomarker for Transplant-Associated Thrombotic Microangiopathy","volume":"12","author":"Okamura","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1182\/bloodadvances.2018020321","article-title":"Complement-mediated thrombotic microangiopathy as a link between endothelial damage and ster-oid-refractory GVHD","volume":"2","author":"Wall","year":"2018","journal-title":"Blood Adv."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/j.bbmt.2013.09.005","article-title":"Serum Neutrophil Extracellular Trap Levels Predict Thrombotic Microangiopathy after Allogeneic Stem Cell Transplantation","volume":"19","author":"Arai","year":"2013","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1038\/bmt.2017.119","article-title":"Transplant-associated thrombotic microangiopathy is an endothelial complication associated with re-fractoriness of acute GvHD","volume":"52","author":"Zeisbrich","year":"2017","journal-title":"Bone Marrow Transpl."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.bbmt.2013.10.014","article-title":"Improved Survival with Ursodeoxycholic Acid Prophylaxis in Allogeneic Stem Cell Transplantation: Long-Term Follow-Up of a Randomized Study","volume":"20","author":"Ruutu","year":"2013","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/s41409-019-0703-1","article-title":"EASIX and mortality after allogeneic stem cell transplantation","volume":"55","author":"Luft","year":"2019","journal-title":"Bone Marrow Transplant."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1586\/ehm.12.18","article-title":"Defibrotide for the treatment of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation","volume":"5","author":"Corbacioglu","year":"2012","journal-title":"Expert Rev. Hematol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/j.bbmt.2017.05.013","article-title":"Acquired Complement Regulatory Gene Mutations and Hematopoietic Stem Cell Transplant\u2013Related Thrombotic Microangiopathy","volume":"23","author":"Ardissino","year":"2017","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1182\/blood-2017-05-782870","article-title":"Circulating dsDNA, endothelial injury, and complement activation in thrombotic microangiopathy and GVHD","volume":"130","author":"Gloude","year":"2017","journal-title":"Blood"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1038\/bmt.2015.161","article-title":"The potential role of HLA-DRB1*11 in the development and outcome of haematopoietic stem cell trans-plantation-associated thrombotic microangiopathy","volume":"50","author":"Balassa","year":"2015","journal-title":"Bone Marrow Transpl."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/j.1538-7836.2009.03692.x","article-title":"Human leukocyte antigen association in idiopathic thrombotic thrombocytopenic purpura: Evidence for an immunogenetic link","volume":"8","author":"Scully","year":"2010","journal-title":"J. Thromb. Haemost."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.bbmt.2005.06.001","article-title":"Blood and Marrow Transplant Clinical Trials Network Toxicity Committee Consensus Summary: Thrombotic Microangiopathy after Hematopoietic Stem Cell Transplantation","volume":"11","author":"Ho","year":"2005","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3324\/haematol.10699","article-title":"Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: Results of a consensus process by an International Working Group","volume":"92","author":"Ruutu","year":"2007","journal-title":"Haematologica"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.bbmt.2012.10.006","article-title":"Thrombotic microangiopathy associated with sirolimus level after allogeneic hematopoietic cell trans-plantation with tacrolimus\/sirolimus-based graft-versus-host disease prophylaxis","volume":"19","author":"Shayani","year":"2013","journal-title":"Biol. Blood Marrow Transpl."},{"key":"ref_40","first-page":"1049","article-title":"Complement blockade for TA-TMA: Lessons learned from large pediatric cohort treated with eculizumab","volume":"135","author":"Jodele","year":"2020","journal-title":"Blood"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1007\/s12325-022-02184-4","article-title":"The Role of Complement in HSCT-TMA: Basic Science to Clinical Practice","volume":"39","author":"Meri","year":"2022","journal-title":"Adv. Ther."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.blre.2014.11.001","article-title":"A new paradigm: Diagnosis and management of HSCT-associated thrombotic microangiopathy as mul-ti-system endothelial injury","volume":"29","author":"Jodele","year":"2015","journal-title":"Blood Rev."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/j.bbmt.2008.09.015","article-title":"Albuminuria in Hematopoietic Cell Transplantation Patients: Prevalence, Clinical Associations, and Impact on Survival","volume":"14","author":"Hingorani","year":"2008","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/bmt.2013.197","article-title":"Urinary cytokines after HCT: Evidence for renal inflammation in the pathogenesis of proteinuria and kidney disease","volume":"49","author":"Hingorani","year":"2013","journal-title":"Bone Marrow Transplant."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s12185-019-02750-7","article-title":"Intestinal thrombotic microangiopathy: A distinct entity in the spectrum of graft-versus-host disease","volume":"110","author":"Gavriilaki","year":"2019","journal-title":"Int. J. Hematol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1016\/j.bbmt.2015.06.016","article-title":"Histologic Features of Intestinal Thrombotic Microangiopathy in Pediatric and Young Adult Patients after Hematopoietic Stem Cell Transplantation","volume":"21","author":"Warren","year":"2015","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1038\/s41409-020-0880-y","article-title":"Histologic features of hematopoietic stem cell transplant-associated thrombotic microangiopathy are best percepted in deep skin biopsies and renal biopsies, while showing a significant overlap with changes related to severe acute graft-versus-host disease in gastrointestinal biopsies","volume":"55","author":"Ehmann","year":"2020","journal-title":"Bone Marrow Transplant."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.bbmt.2019.08.025","article-title":"Distribution of Transplantation-Associated Thrombotic Microangiopathy (TA-TMA) and Comparison between Renal TA-TMA and Intestinal TA-TMA: Autopsy Study","volume":"26","author":"Yamada","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/bmt.2008.419","article-title":"Clinicopathological manifestations and treatment of intestinal transplant-associated microangiopathy","volume":"44","author":"Inamoto","year":"2009","journal-title":"Bone Marrow Transplant."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e27912","DOI":"10.1002\/pbc.27912","article-title":"Successful treatment with eculizumab for posterior reversible encephalopathy syndrome due to underlying transplant-associated thrombotic microangiopathy in patients transplanted for sickle cell disease","volume":"66","author":"Bhunia","year":"2019","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/j.bbmt.2013.07.017","article-title":"Pulmonary Hypertension after Hematopoietic Stem Cell Transplantation","volume":"19","author":"Dandoy","year":"2013","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"ESC Scientific Document Group (2016). 2015 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), Interna-tional Society for Heart and Lung Transplantation (ISHLT). Eur. Heart J., 37, 67\u2013119.","DOI":"10.1093\/eurheartj\/ehv317"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1080\/17474086.2021.1960816","article-title":"Transplant-associated thrombotic microangiopathy: Elucidating prevention strategies and identifying high-risk patients","volume":"14","author":"Jodele","year":"2021","journal-title":"Expert Rev. Hematol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/0022-4804(89)90026-7","article-title":"Cyclosporine inhibits endothelial cell prostacyclin production","volume":"46","author":"Rosenthal","year":"1989","journal-title":"J. Surg. Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1097\/00007890-198804000-00025","article-title":"Cyclosporine suppression of endothelial prostacyclin generation","volume":"45","author":"Voss","year":"1988","journal-title":"Transplantation"},{"key":"ref_56","first-page":"476","article-title":"Inhibitory effect of cyclosporin A and FK506 on nitric oxide production by cultured macrophages. Evidence of a direct effect on nitric oxide synthase activity","volume":"84","author":"Conde","year":"1995","journal-title":"Immunology"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/sj.bmt.1705454","article-title":"Replacement of calcineurin inhibitors with daclizumab in patients with transplantation-associated micro-angiopathy or renal insufficiency associated with graft-versus-host disease","volume":"38","author":"Wolff","year":"2006","journal-title":"Bone Marrow Transpl."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1182\/blood-2011-02-321315","article-title":"Small vessels, big trouble in the kidneys and beyond: Hematopoietic stem cell transplantation\u2013associated thrombotic microangiopathy","volume":"118","author":"Laskin","year":"2011","journal-title":"Blood"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1046\/j.1365-2141.2001.02699.x","article-title":"The clinical features, risk factors and outcome of thrombotic thrombocytopenic purpura occurring after bone marrow transplantation","volume":"113","author":"Fuge","year":"2001","journal-title":"Br. J. Haematol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/sj.bmt.1702849","article-title":"Thrombotic thrombocytopenic purpura-like syndromes following bone marrow transplantation: An analysis of associated conditions and clinical outcomes","volume":"27","author":"Roy","year":"2001","journal-title":"Bone Marrow Transplant."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1046\/j.1537-2995.2000.40080896.x","article-title":"Complications of plasma exchange in 71 consecutive patients treated for clinically suspected thrombotic thrombocytopenic purpura-hemolytic-uremic syndrome","volume":"40","author":"Rizvi","year":"2000","journal-title":"Transfusion"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/j.1537-2995.2008.02030.x","article-title":"Complications of plasma exchange in patients treated for thrombotic thrombocytopenic purpura. IV. An additional study of 43 consecutive patients, 2005 to 2008","volume":"49","author":"Nguyen","year":"2009","journal-title":"Transfusion"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1038\/sj.leu.2403004","article-title":"Defibrotide reduces procoagulant activity and increases fibrinolytic properties of endothelial cells","volume":"17","author":"Falanga","year":"2003","journal-title":"Leukemia"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2165\/00003495-199345020-00007","article-title":"A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in vascular disorders","volume":"45","author":"Palmer","year":"1993","journal-title":"Drugs"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s12288-017-0904-y","article-title":"Successful Treatment of Transplant Associated Thrombotic Microangiopathy (TA-TMA) with Low Dose Defibrotide","volume":"34","author":"Devadas","year":"2017","journal-title":"Indian J. Hematol. Blood Transfus."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/bmt.2016.351","article-title":"Use of defibrotide to treat transplant-associated thrombotic microangiopathy: A retrospective study of the Paediatric Diseases and Inborn Errors Working Parties of the European Society of Blood and Marrow Transplantation","volume":"52","author":"Yeates","year":"2017","journal-title":"Bone Marrow Transplant."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1016\/j.bbmt.2017.08.019","article-title":"Thrombotic Microangiopathy after Allogeneic Stem Cell Transplantation: A Comparison of Eculizumab Therapy and Conventional Therapy","volume":"23","author":"Bohl","year":"2017","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Higham, C.S., Shimano, K.A., Melton, A., Kharbanda, S., Chu, J., Dara, J., Winestone, L.E., Hermiston, M.L., Huang, J.N., and Dvorak, C.C. (2022). A pilot trial of prophylactic defibrotide to prevent serious thrombotic microangiopathy in high-risk pediatric patients. Pediatr. Blood Cancer, 69.","DOI":"10.1002\/pbc.29641"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1097\/TP.0000000000000601","article-title":"Use of Eculizumab in Patients With Allogeneic Stem Cell Transplant-Associated Thrombotic Mi-croangiopathy: A Study From the SFGM-TC","volume":"99","author":"Galambrun","year":"2015","journal-title":"Transplantation"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"3519","DOI":"10.1111\/trf.15534","article-title":"Approaching treatment of transplant-associated thrombotic Microangiopathy from two directions with Ecu-lizumab and transitioning from Tacrolimus to Sirolimus","volume":"59","author":"Jan","year":"2019","journal-title":"Transfusion"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.bbmt.2013.12.565","article-title":"Eculizumab Therapy in Children with Severe Hematopoietic Stem Cell Transplantation\u2013Associated Thrombotic Microangiopathy","volume":"20","author":"Jodele","year":"2013","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/j.cmi.2018.02.002","article-title":"ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: An infectious diseases perspective (Soluble immune effector molecules [II]: Agents targeting interleukins, immunoglobulins and complement factors)","volume":"24","author":"Winthrop","year":"2018","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1440-1827.2010.02608.x","article-title":"Renal thrombotic microangiopathy associated with chronic humoral graft versus host disease after hemato-poietic stem cell transplantation","volume":"61","author":"Mii","year":"2011","journal-title":"Pathol. Int."},{"key":"ref_74","first-page":"E39","article-title":"Successful early intervention for hyperacute transplant-associated thrombotic microangiopathy following pediatric hematopoietic stem cell transplantation","volume":"16","author":"Jodele","year":"2010","journal-title":"Pediatr. Transplant."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1200\/JCO.21.02389","article-title":"Narsoplimab, a Mannan-Binding Lectin-Associated Serine Protease-2 Inhibitor, for the Treatment of Adult Hematopoietic Stem-Cell Transplantation-Associated Thrombotic Microangiopathy","volume":"40","author":"Khaled","year":"2022","journal-title":"J. Clin. Oncol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/2\/1159\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:01:50Z","timestamp":1760119310000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/2\/1159"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,6]]},"references-count":75,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["ijms24021159"],"URL":"https:\/\/doi.org\/10.3390\/ijms24021159","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,6]]}}}